NO303784B1 - Syntetiske isohirudiner med forbedret stabilitet, vektorer, fremgangsmÕte for fremstilling av isohirudiner og anvendelse derav - Google Patents
Syntetiske isohirudiner med forbedret stabilitet, vektorer, fremgangsmÕte for fremstilling av isohirudiner og anvendelse derav Download PDFInfo
- Publication number
- NO303784B1 NO303784B1 NO924681A NO924681A NO303784B1 NO 303784 B1 NO303784 B1 NO 303784B1 NO 924681 A NO924681 A NO 924681A NO 924681 A NO924681 A NO 924681A NO 303784 B1 NO303784 B1 NO 303784B1
- Authority
- NO
- Norway
- Prior art keywords
- glu
- isohirudins
- ala
- plasmid
- gin
- Prior art date
Links
- 239000013598 vector Substances 0.000 title claims description 17
- 238000000034 method Methods 0.000 title claims description 13
- 238000002360 preparation method Methods 0.000 title claims description 8
- 150000001413 amino acids Chemical group 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 241000588724 Escherichia coli Species 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 238000005341 cation exchange Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 238000003916 acid precipitation Methods 0.000 claims description 2
- 238000011097 chromatography purification Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- JHFNSBBHKSZXKB-VKHMYHEASA-N Asp-Gly Chemical group OC(=O)C[C@H](N)C(=O)NCC(O)=O JHFNSBBHKSZXKB-VKHMYHEASA-N 0.000 abstract description 4
- 238000010626 work up procedure Methods 0.000 abstract description 2
- 229940102223 injectable solution Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 description 50
- 239000012634 fragment Substances 0.000 description 32
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 29
- 108010007267 Hirudins Proteins 0.000 description 24
- 102000007625 Hirudins Human genes 0.000 description 23
- 229940006607 hirudin Drugs 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 16
- 229940024606 amino acid Drugs 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 14
- 239000000047 product Substances 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 9
- XYWBJDRHGNULKG-OUMQNGNKSA-N desirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 XYWBJDRHGNULKG-OUMQNGNKSA-N 0.000 description 9
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000006227 byproduct Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000010276 construction Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 108010073652 desirudin Proteins 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 239000002831 pharmacologic agent Substances 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 239000012614 Q-Sepharose Substances 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000011026 diafiltration Methods 0.000 description 3
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 2
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 2
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 238000007169 ligase reaction Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- UDPGUMQDCGORJQ-UHFFFAOYSA-N (2-chloroethyl)phosphonic acid Chemical compound OP(O)(=O)CCCl UDPGUMQDCGORJQ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101100313763 Arabidopsis thaliana TIM22-2 gene Proteins 0.000 description 1
- 101100228200 Caenorhabditis elegans gly-5 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- -1 Glu33 Proteins 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 241000237902 Hirudo medicinalis Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 101100506776 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) hir-1 gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000004690 coupled electron pair approximation Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- VBEGHXKAFSLLGE-UHFFFAOYSA-N n-phenylnitramide Chemical compound [O-][N+](=O)NC1=CC=CC=C1 VBEGHXKAFSLLGE-UHFFFAOYSA-N 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Extrusion Moulding Of Plastics Or The Like (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4140381A DE4140381A1 (de) | 1991-12-07 | 1991-12-07 | Neue synthetische isohirudine mit verbesserter stabilitaet |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO924681D0 NO924681D0 (no) | 1992-12-04 |
| NO924681L NO924681L (no) | 1993-06-08 |
| NO303784B1 true NO303784B1 (no) | 1998-08-31 |
Family
ID=6446509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO924681A NO303784B1 (no) | 1991-12-07 | 1992-12-04 | Syntetiske isohirudiner med forbedret stabilitet, vektorer, fremgangsmÕte for fremstilling av isohirudiner og anvendelse derav |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US5286714A (sk) |
| EP (1) | EP0549915B1 (sk) |
| JP (1) | JP3352128B2 (sk) |
| KR (1) | KR100249577B1 (sk) |
| CN (1) | CN1036934C (sk) |
| AT (1) | ATE152125T1 (sk) |
| AU (1) | AU662574B2 (sk) |
| CA (1) | CA2084552C (sk) |
| DE (2) | DE4140381A1 (sk) |
| DK (1) | DK0549915T3 (sk) |
| ES (1) | ES2100263T3 (sk) |
| FI (1) | FI98309C (sk) |
| GR (1) | GR3023640T3 (sk) |
| HU (2) | HU214701B (sk) |
| IL (1) | IL103987A (sk) |
| NO (1) | NO303784B1 (sk) |
| NZ (1) | NZ245374A (sk) |
| PH (1) | PH30345A (sk) |
| TW (1) | TW215442B (sk) |
| ZA (1) | ZA929424B (sk) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19543737A1 (de) * | 1995-11-24 | 1997-05-28 | Hoechst Ag | Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices |
| US5733732A (en) * | 1996-01-03 | 1998-03-31 | University Of Iowa Research Foundation | Methods for detecting primary adhalinopathy |
| KR20000070338A (ko) * | 1997-01-20 | 2000-11-25 | 나가시마 카쭈시게, 노미야마 아키히코 | 펩티드의 안정화 방법 및 당해 방법을 이용한 펩티드 함유 동결건조 의약조성물 |
| DE19944870A1 (de) | 1999-09-18 | 2001-03-29 | Aventis Pharma Gmbh | Signalsequenzen zur Herstellung von Leu-Hirudin über Sekretion durch E. coli in das Kulturmedium |
| US7202059B2 (en) * | 2001-02-20 | 2007-04-10 | Sanofi-Aventis Deutschland Gmbh | Fusion proteins capable of being secreted into a fermentation medium |
| US7638618B2 (en) | 2001-02-20 | 2009-12-29 | Sanofi-Aventis Deutschland Gmbh | Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest |
| CN1328380C (zh) * | 2001-09-24 | 2007-07-25 | 天津天士力制药股份有限公司 | 高效表达水蛭素及其生产方法 |
| DE602005023429D1 (de) * | 2004-10-19 | 2010-10-21 | Lonza Ag | Verfahren zur festphasen-peptidsynthese |
| CN102286098B (zh) * | 2011-08-18 | 2013-09-04 | 周维官 | 一种天然水蛭素的生产方法 |
| CN113072639B (zh) * | 2021-03-16 | 2023-07-04 | 宁波博睿瀚达生物科技有限公司 | 一种高纯度重组水蛭素的纯化方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3342139A1 (de) * | 1983-11-22 | 1985-05-30 | Ciba-Geigy Ag, Basel | Desulfatohirudine, verfahren zu ihrer herstellung und pharmazeutische mittel |
| CA1341417C (fr) * | 1984-03-27 | 2003-01-21 | Paul Tolstoshev | Vecteurs d'expression de l'hirudine, cellules transformees et procede de preparation de l'hirudine |
| DE3438296A1 (de) * | 1984-04-18 | 1985-11-07 | Hoechst Ag, 6230 Frankfurt | Neue polypeptide mit blutgerinnungshemmender wirkung, verfahren zu deren herstellung bzw. gewinnung, deren verwendung und diese enthaltende mittel |
| ATE64956T1 (de) * | 1984-06-14 | 1991-07-15 | Ciba Geigy Ag | Verfahren zur herstellung von thrombininhibitoren. |
| DE3429430A1 (de) * | 1984-08-10 | 1986-02-20 | Hoechst Ag, 6230 Frankfurt | Gentechnologisches verfahren zur herstellung von hirudin und mittel zur durchfuehrung dieses verfahrens |
| DE3445532A1 (de) * | 1984-12-13 | 1986-06-19 | Plantorgan Werk Heinrich G.E. Christensen, KG, 2903 Bad Zwischenahn | Hirudin-pa, desulfatohirudine-pa, verfahren zur herstellung und pharmazeutische mittel, die diese wirkstoffe enthalten |
| DE3506992A1 (de) * | 1985-02-27 | 1986-08-28 | Plantorgan Werk Heinrich G.E. Christensen, KG, 2903 Bad Zwischenahn | Modifizierte hirudine, verfahren zu deren herstellung und pharmazeutische mittel, die diese wirkstoffe enthalten |
| DE3738541A1 (de) * | 1987-11-13 | 1989-05-24 | Hoechst Ag | Verfahren zur isolierung und reinigung von hirudin |
| EP0324712B1 (de) * | 1985-04-11 | 1993-04-07 | Hoechst Aktiengesellschaft | Hirudin-Derivat |
| FR2593518B1 (fr) * | 1985-05-02 | 1989-09-08 | Transgene Sa | Vecteurs d'expression et de secretion de l'hirudine par les levures transformees |
| DE3689525D1 (de) * | 1985-07-17 | 1994-02-24 | Hoechst Ag | Neue Polypeptide mit blutgerinnungshemmender Wirkung, Verfahren zu deren Herstellung bzw. Gewinnung, deren Verwendung und diese enthaltende Mittel. |
| DE3541856A1 (de) * | 1985-11-27 | 1987-06-04 | Hoechst Ag | Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens |
| KR900003028B1 (ko) * | 1985-12-13 | 1990-05-04 | 미쓰비시 뎅기 가부시끼가이샤 | 반도체 집적회로장치 |
| AU604925B2 (en) * | 1988-02-23 | 1991-01-03 | Schering Aktiengesellschaft | A hirudin derivative |
| DE3835815A1 (de) * | 1988-10-21 | 1990-04-26 | Hoechst Ag | Neue isohirudine |
| DE4009268A1 (de) * | 1990-03-22 | 1991-09-26 | Consortium Elektrochem Ind | Sekretion von hirudinderivaten |
-
1991
- 1991-12-07 DE DE4140381A patent/DE4140381A1/de not_active Withdrawn
-
1992
- 1992-11-18 TW TW081109204A patent/TW215442B/zh not_active IP Right Cessation
- 1992-12-03 US US07/985,110 patent/US5286714A/en not_active Expired - Lifetime
- 1992-12-03 FI FI925497A patent/FI98309C/fi not_active IP Right Cessation
- 1992-12-04 DE DE59208398T patent/DE59208398D1/de not_active Expired - Lifetime
- 1992-12-04 CA CA002084552A patent/CA2084552C/en not_active Expired - Lifetime
- 1992-12-04 HU HU9203838A patent/HU214701B/hu unknown
- 1992-12-04 EP EP92120727A patent/EP0549915B1/de not_active Expired - Lifetime
- 1992-12-04 JP JP32525592A patent/JP3352128B2/ja not_active Expired - Fee Related
- 1992-12-04 HU HU9203838A patent/HU9203838D0/hu unknown
- 1992-12-04 AT AT92120727T patent/ATE152125T1/de active
- 1992-12-04 NZ NZ245374A patent/NZ245374A/en not_active IP Right Cessation
- 1992-12-04 ES ES92120727T patent/ES2100263T3/es not_active Expired - Lifetime
- 1992-12-04 DK DK92120727.0T patent/DK0549915T3/da active
- 1992-12-04 IL IL10398792A patent/IL103987A/xx not_active IP Right Cessation
- 1992-12-04 AU AU29920/92A patent/AU662574B2/en not_active Expired
- 1992-12-04 NO NO924681A patent/NO303784B1/no not_active IP Right Cessation
- 1992-12-04 ZA ZA929424A patent/ZA929424B/xx unknown
- 1992-12-05 KR KR1019920023378A patent/KR100249577B1/ko not_active IP Right Cessation
- 1992-12-07 PH PH45381A patent/PH30345A/en unknown
- 1992-12-07 CN CN92114142A patent/CN1036934C/zh not_active Expired - Lifetime
-
1993
- 1993-07-29 US US08/099,053 patent/US5316947A/en not_active Expired - Lifetime
-
1995
- 1995-05-30 US US08/452,829 patent/US5616476A/en not_active Expired - Lifetime
-
1997
- 1997-05-30 GR GR970401286T patent/GR3023640T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US5286714A (en) | 1994-02-15 |
| FI925497A0 (fi) | 1992-12-03 |
| DE59208398D1 (de) | 1997-05-28 |
| JPH05310789A (ja) | 1993-11-22 |
| HUT70452A (en) | 1995-10-30 |
| AU662574B2 (en) | 1995-09-07 |
| EP0549915B1 (de) | 1997-04-23 |
| US5316947A (en) | 1994-05-31 |
| DK0549915T3 (da) | 1997-10-20 |
| ATE152125T1 (de) | 1997-05-15 |
| IL103987A (en) | 1997-02-18 |
| CA2084552C (en) | 2007-03-27 |
| GR3023640T3 (en) | 1997-08-29 |
| AU2992092A (en) | 1993-06-10 |
| KR100249577B1 (ko) | 2000-03-15 |
| HU214701B (hu) | 1998-08-28 |
| TW215442B (sk) | 1993-11-01 |
| FI925497A (fi) | 1993-06-08 |
| CN1073978A (zh) | 1993-07-07 |
| EP0549915A1 (de) | 1993-07-07 |
| IL103987A0 (en) | 1993-05-13 |
| FI98309B (fi) | 1997-02-14 |
| NZ245374A (en) | 1995-04-27 |
| DE4140381A1 (de) | 1993-06-09 |
| FI98309C (fi) | 1997-05-26 |
| ZA929424B (en) | 1993-05-27 |
| US5616476A (en) | 1997-04-01 |
| NO924681L (no) | 1993-06-08 |
| ES2100263T3 (es) | 1997-06-16 |
| CA2084552A1 (en) | 1993-06-08 |
| CN1036934C (zh) | 1998-01-07 |
| NO924681D0 (no) | 1992-12-04 |
| JP3352128B2 (ja) | 2002-12-03 |
| HU9203838D0 (en) | 1993-03-29 |
| PH30345A (en) | 1997-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2551551B2 (ja) | デスルファトヒルジン、その製造及びそれを含む製薬組成物 | |
| US5149792A (en) | Platelet-derived growth factor B chain analogs | |
| US4894436A (en) | Homologs of aprotinin produced from a recombinant host, process expression vector and recombinant host therefor and pharaceutical use thereof | |
| US5446131A (en) | Thrombin receptor antagonists | |
| AU646014B2 (en) | Novel platelet-derived growth factor B chain analogs and method for homogeneous production thereof | |
| JP3043764B2 (ja) | ミニ‐プロインシュリン、その製造および使用 | |
| CN113121705B (zh) | 用于制备短肽混合物的融合蛋白、目的多肽、短肽混合物的制备方法及应用 | |
| NO172441B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive insulinforbindelser | |
| NO303784B1 (no) | Syntetiske isohirudiner med forbedret stabilitet, vektorer, fremgangsmÕte for fremstilling av isohirudiner og anvendelse derav | |
| Johnson et al. | Purification and characterization of different types of exfoliative toxin from Staphylococcus aureus | |
| Dunwiddie et al. | Site-directed analysis of the functional domains in the factor Xa inhibitor tick anticoagulant peptide: identification of two distinct regions that constitute the enzyme recognition sites | |
| AU651083B2 (en) | Production of biologically active platelet-derived growth factor from high expression host cell systems | |
| Bassuk et al. | Expression of biologically active human SPARC inEscherichia coli | |
| Hidaka et al. | Disulfide linkages in a heat-stable enterotoxin (STP) produced by a porcine strain of enterotoxigenic Escherichia coli. | |
| AU661515B2 (en) | Polypeptide, DNA fragment encoding the same, drug composition containing the same and process for producing the same | |
| Caccia et al. | Stabilization of recombinant human basic fibroblast growth factor by chemical modifications of cysteine residues | |
| JPH10507929A (ja) | 高い安定性と生物活性をもつ酸性繊維芽細胞増殖因子の類似体 | |
| Märki et al. | Recombinant hirudin: genetic engineering and structure analysis | |
| Philipp et al. | Mutational analysis of disulfide bonds in the trypsin‐reactive subdomain of a Bowman‐Birk‐type inhibitor of trypsin and chymotrypsin: Cooperative versus autonomous refolding of subdomains | |
| Ikemura et al. | Heat-stable enterotoxin (STh) of human enterotoxigenic Escherichia coli (strain SK-1). Structure-activity relationship. | |
| JPH05308988A (ja) | 新規ポリペプチド、新規ｄｎａ、新規ベクター、新規形質転換体、新規医薬組成物、および新規ポリペプチドの製造方法 | |
| WO2002068457A2 (en) | Antiangiogenic peptides derived from endostatin | |
| US5756462A (en) | Pore forming peptides from Geolycosa riogrande | |
| Okada et al. | Synthesis of a trihexacontapeptide corresponding to the sequence 8–70 of eglin c and studies on the relationship between the structure and the inhibitory activity against human leukocyte elastase, cathepsin G and α‐chymotrypsin | |
| Suzuki et al. | Purification and characterization of a signal peptide, a product of protein secretion across the cytoplasmic membrane of Escherichia coli |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |